Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

Table 1 Disease characteristics among patients who received radiotherapy during their treatment course (RT) and who didn’t (Non-RT), as well as in the whole population

	ALL patients n (%)	Non-RT n (%)	RT n (%)	p
Age (years)				0.958
Median	50	49	50
Range	21–75	28–75	21–68
Sex				0.079
Male	55 (59.1)	26 (51.0)	29 (69.0)
Female	38 (40.9)	25 (49.0)	13 (31.0)
Histology				0.452
Adenocarcinoma	90 (96.8)	50 (98.0)	40 (95.2)
Non-adenocarcinoma	3 (3.2)	1 (2.0)	2 (4.8)
ECOG				0.814
0–1	88 (94.6)	48 (94.1)	40 (95.2)
2	5 (5.4)	3 (5.9)	2 (4.8)
Primary tumor Size (cm)				0.390
Median	3.5	3.5	3.0
Range	0.0–8.0	0.0–8.0	0.0–7.9
T stage				0.841
T1–2	52 (55.9)	29 (56.9)	23 (54.8)
T3–4	41 (44.1)	22 (43.1)	19 (45.2)
N stage				0.513
N0	9 (9.7)	4 (7.8)	5 (11.9)
N1–3	84 (90.3)	47 (92.2)	37 (88.1)
Number of metastatic organs				0.055
1–2	66 (71.0)	32 (62.7)	34 (81.0)
≥ 3	27 (29.0)	19 (37.3)	8 (19.0)
Number of metastatic lesions				0.053
1–5	28 (30.1)	11 (21.6)	17 (40.5)
≥ 6	65 (69.9)	40 (78.4)	25 (59.5)
Presence of lung metastases				0.069
Yes	24 (25.8)	17 (33.3)	7 (16.7)
No	69 (74.2)	34 (67.7)	35 (83.3)
Presence of liver metastases				0.119
Yes	15 (16.1)	11 (21.6)	4 (9.5)
No	78 (83.9)	40 (78.4)	38 (90.5)
Presence of brain metastases				0.010
Yes	35 (37.6)	13 (25.5)	22 (52.4)
No	58 (62.4)	38 (74.5)	20 (47.6)
Presence of adrenal metastases				0.086
Yes	13 (14.0)	10 (19.6)	3 (7.1)
No	80 (86.0)	41 (80.4)	39 (92.9)
Presence of Bone metastases				0.698
Yes	33 (35.5)	19 (37.3)	14 (33.3)
No	60 (64.5)	32 (62.7)	28 (66.7)

ISSN: 1748-717X